Skip to content


Cablivi (caplacizumab) is an antibody pharmaceutical. Caplacizumab was first approved as Cablivi on 2018-08-30. It has been approved in Europe to treat thrombotic thrombocytopenic purpura. The pharmaceutical is active against von Willebrand factor.
Trade Name Cablivi
Common Name Caplacizumab
Indication thrombotic thrombocytopenic purpura
Drug Class Monoclonal antibodies: humanized, cardiovascular indications
Get full access now